What is PD-L1 testing and why is it important

PD-L1 testing is a laboratory test that looks for a protein called PD-L1 on the surface of cancer cells. PD-L1 (programmed death-ligand 1) is a protein that helps cancer cells hide from the immune system. When PD-L1 binds to a receptor called PD-1 on immune cells (T cells), it tells the immune cells to stand down, preventing them from attacking the cancer.

Why is PD-L1 testing important?
This test helps doctors understand whether immunotherapy drugs, specifically immune checkpoint inhibitors, might be effective for your cancer. According to the NCCN Guidelines for Patients, if your tumor has a high level of PD-L1 (meaning at least 50% of cancer cells have PD-L1), you are more likely to respond well to certain immunotherapy drugs like pembrolizumab. If the PD-L1 level is low or absent, other treatment options might be considered, as the response to immunotherapy may be less likely.

How does PD-L1 testing influence treatment?
The results guide treatment decisions. For example, in non-small cell lung cancer (NSCLC), high PD-L1 levels often mean that immunotherapy alone or combined with chemotherapy could be effective. Conversely, low or no PD-L1 expression might lead your doctor to recommend different treatments, such as chemotherapy or targeted therapy.

In summary:
PD-L1 testing is a way to measure a protein that helps cancer evade the immune system. It is important because it helps determine whether immunotherapy drugs are likely to work for your specific cancer, guiding personalized treatment plans.

Sources:

• NCCN Guidelines for Patients: Metastatic Non-Small Cell Lung Cancer (2024)
• American Cancer Society recommendations on immunotherapy and PD-L1 testing